Navigation Links
Reportlinker Adds Pharmaceutical Key Trends 2010

NEW YORK, Dec. 14, 2010 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Pharmaceutical Key Trends 2010

IntroductionPharma faces a number of key resistors to growth including the impending 2011 patent cliff which is set to erode $78 billion in global branded sales from drugs facing patent expiry over the 201014 period (plus $32 billion from continued erosion of already expired brands). Price cuts, reimbursement restrictions and growing regulatory pressure are further set to limit sales growth going forward.

Scope* Overview of the key drivers and resistors facing Pharma, Biotech and generics players out to 2014

* Analysis of recent regulatory changes in the US, EU and emerging markets and their impact on pricing and reimbursement, drug development and marketing

* Examination of key global and country-specific issues facing both biosimilars and generics players

* Assessment of the impact of the global economic downturn on the Pharma and Biotech sectors and their respective counter strategies

HighlightsAnnual sales growth of pharmaceuticals in the emerging markets is already double-digit, providing a key opportunity for Pharma. Revenue streams in these markets can be derived from launching branded off-patent drugs, branded generics, and local brands owned or licensed by the acquiring pharma company.

Pharma is moving away from the "me-too" and increasingly genericized primary care market towards more high value biologic therapies in secondary care as well as more niche markets; markets with little or no existing competition, and which despite their smaller size (in terms of patient numbers) are still commercially attractive.

To maintain profitability in the face of slowing sales to 2014, pharma companies have implemented a number of cost-cutting measures (in addition to strategic repositioning and diversification strategies) in order to boost profitability going forward.

Reasons to Purchase* Examine the combined prescription drug sales forecasts for the top 50 Pharma out to 2014 by molecule type, product source, geography and therapy area

* Identify the key factors impacting Pharma's R&D productivity as well as the solutions companies are implementing to strengthen their R&D efforts

* Assess key drivers behind Pharma's M&A activity and its role in boosting profits by opening up new access to new markets as well as cutting costs


About the Healthcare Strategic Analysis Team 2

1. About this report 3

Data sourcing – the PharmaVitae Explorer database 3

Chapter structure 4

Glossary 5

Related reports 5

Upcoming related reports 5

2. Executive Summary 6

Key drivers and resistors facing Pharma 6

Resistors for Pharma 7

Drivers for Pharma 14

Neutral for Pharma 23

Key drivers and resistors facing generics and biosimilars companies 26

Key drivers and resistors facing Biotech 28

3. Healthcare Systems and Regulations 32

Expansion of healthcare provision top of the agenda of many countries 32

US health reform set to change the country's healthcare landscape 36

The FDA is set on restoring its reputation 62

Drug prices suffer in Japan 69

Five major EU markets – cost-containment pressures mount 72

EU legislation focused on streamlining regulatory processes 80

New healthcare initiatives in the emerging markets are tackling growing costs 83

Brazil's ANVISA may hamper the domestics growth of multinational pharma companies 85

Russia enhances regulations to boost growth of the domestic pharma industry 87

India tackles growing healthcare expenditure by tightening price controls and increasing access to generic drugs 90

China's healthcare reforms will expand the domestic market but may create challenges for foreign companies 92

4. Generics and Biosimilars 95

The generics market 96

The biosimilars market 117

5. Recession and Recovery 131


Pharmaceutical Key Trends 2010 DMHC2599

Largely insulated from the recession Pharma's key threat is the patent cliff 131

Biotech emerges from its funding crisis 138

6. Prescription Drug Market Outlook 146

Definitions – launch, core, expiry 146

Drivers and resistors for sales growth of the top 50 pharma companies out to 2014 146

7. Research and Development 164

Pharma continues to battle with R&D issues 164

Pharma's R&D cost-cutting exercise is only a short-term solution 168

Pharma's late-stage deal activity set to increase to help offset the patent cliff 170

Pharma's level of early-stage R&D collaboration intensifies 171

Outsourcing set to rise following initial cost-cutting exercises implemented during the economic downturn 173

Pharma sharpens its focus on secondary care indications through high value biologic therapies as the patent cliff looms 175

Personalized medicine and stem cell technology are key strategies in the commercialization of niche indications 183

Pharma embraces low cost late-stage lifecycle management strategies 187

8. Mergers and Acquisitions 192

M&A will remain a central strategy for Pharma 192

M&A deals to increase scale and cut costs 196

M&A deals to target high growth therapeutic markets 199

M&A deals to target high growth geographic markets 201

M&A deals to increase pharma focus or diversify into other healthcare markets 205

9. Bibliography 212

Executive Summary 212

Healthcare Systems and Regulations 212

Generics and Biosimilars 223

Recession and Rrecovery 232

Prescription Drug Market Outlook 235

Research and Development 235

Mergers and Acquisitions 241


Exchange rates 244

US healthcare reform model 245

About Datamonitor 253


Datamonitor consulting 254

Disclaimer 256

To order this report:Pharmaceutical Industry: Pharmaceutical Key Trends 2010

Pharmaceutical Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Contact:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
(Date:12/1/2015)... 1, 2015 A federal court has denied the ... a lawsuit filed by the Pharmaceutical Care Management Association (PCMA) ... a new law that forces employers and consumers to pay ... Arkansas must now defend a law that raises ... and CEO Mark Merritt . --> ...
(Date:12/1/2015)... 2015  Athletic apparel company Tommie Copper ... pay $1.35 million to settle Federal Trade Commission ... compression clothing would relieve severe and chronic pain ... Tommie Copper,s proposed settlement ... its founder and chairman Thomas Kallish ...
(Date:12/1/2015)... , Dec. 1, 2015 Assurex ... its GeneSight® Psychotropic test giving healthcare providers an expanded ... decisions for patients suffering from depression, anxiety, bipolar ... behavioral health conditions. i . ... --> With the addition of two new ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of ... latest addition to the devices for sale in the United States. Clarity is ... long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to own ...
(Date:12/1/2015)... ... 01, 2015 , ... PYA’s latest white paper, “ PYA ... main “pain point” for merging or aligning healthcare provider organizations—when mergers and other ... This quick-read guidance suggests that failing to recognize the power of an ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a leader ... leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves as ... significant amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. ...
(Date:12/1/2015)... ... ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has won a tender ... be from the China Disabled Persons’ Federation, a central government association, for nearly 2,000 ... and adults suffering from severe and profound hearing loss . The company holds ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Trust on receiving the 2015 HSJ Acute Sector Innovation Award on November 18th. ... the patient care experience, and propose exciting enhancements to the medical landscape. , ...
Breaking Medicine News(10 mins):